Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Depreciation & Amortization (CF) (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 5.97% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.6 million, a 1.82% decrease, with the full-year FY2024 number at $4.7 million, up 10.68% from a year prior.
  • Depreciation & Amortization (CF) was $1.3 million for Q3 2025 at 4D Molecular Therapeutics, up from $1.2 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.3 million in Q3 2025 to a low of $370000.0 in Q2 2021.
  • A 5-year average of $855842.1 and a median of $1.0 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 160.0% in 2022, then decreased 10.4% in 2025.
  • 4D Molecular Therapeutics' Depreciation & Amortization (CF) stood at $390000.0 in 2021, then skyrocketed by 160.0% to $1.0 million in 2022, then grew by 8.68% to $1.1 million in 2023, then decreased by 0.54% to $1.1 million in 2024, then grew by 15.05% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Depreciation & Amortization (CF) are $1.3 million (Q3 2025), $1.2 million (Q2 2025), and $1.1 million (Q1 2025).